Background
Introduction
Microvascular disease of the retina is a common complication of diabetes, and in populations with Type 1 and Type 2 diabetes the prevalence and progression of retinopathy are clearly related to hyperglycemia. Retinal microvascular lesions typical of diabetic eye disease are also detectable in people without diabetes (Klein, 1992 
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The Early Diabetes Intervention Program (EDIP) was a 5-year prospective randomized controlled trial evaluating the effect of acarbose versus placebo on a background of diet/exercise recommendations to delay progression of fasting glucose in a population with screen-detected, early type 2 diabetes. In the current study, we examined the relationships of retinopathy at baseline to the 5-year progression of fasting plasma glucose. Parallel analyses were performed with measures of nephropathy and neuropathy. recruited from a population at high risk of diabetes, consisting of men and women at least 25 years of age with obesity, a history of gestational diabetes, or a family history of diabetes. They were eligible for the study if they had fasting plasma glucose (FPG) measurement between 105 mg/dl (5.5 mmol/l) and 140 mg/dl (7.8 mmol/l), the diagnostic FPG cutoff for diabetes at time of study inception, plus a 2-h post load plasma glucose (75-g oral glucose tolerance test) measurement ≥200 mg/dl (11.1 mmol/l). Major exclusion criteria included recent treatment for cancer, recent major atherosclerotic events, and chronic infectious diseases. Full details of study inclusion/exclusion criteria have been previously published (Kirkman et al., 2006).
Research Design and Methods
Eligible participants received either acarbose or an identical placebo based on a blinded randomization stratified by site. Acarbose was titrated up to the maximum dose of 100 7 mg three times a day with meals, or the maximum tolerated dose, with matched dose increments among placebo treated individuals. At initiation of randomized study treatment, all subjects received diabetic diet counseling by a registered dietician, and were provided with standard of care recommendations for exercise (Kirkman et al., 2006 ). This advice was reinforced at quarterly visits.
At baseline, each participant completed a standardized medical history, physical examination, electrocardiogram, seven-field fundus photography of both eyes, oral glucose tolerance test, laboratory testing, and 24-h urine collection for measurement of creatinine and albumin concentrations. Participants were seen quarterly for measurement of fasting plasma glucose concentration. The primary outcome for EDIP was the time to transition of fasting plasma glucose >140 mg/dL (7.8 mmol/L), confirmed on a repeat measurement at the next quarterly visit. This event was termed 'progression of fasting glucose', and provided a metric of worsening glycemia amenable to time-to-event analyses. Participants who met criteria for progression did not undergo any further study measurements.
The study protocol was approved by the institutional review boards of both institutions, and each patient signed an informed consent form for screening and for the trial.
Assessment of microvascular disease
Retinal photographs were acquired using a standardized protocol. Seven standard photographic fields were taken in each eye, by experienced retinal photographers who underwent central training and certification by the reading center in Madison WI. A 30º
Zeiss FF series fund camera with Kodachrome 25 Daylight film was used, as specified 8 by the reading center. Printed slide mages were read at a central unit using standardized methodology, with readers blinded to all participant information.
Retinopathy scores and presence or absence of retinopathy was defined according to a simplified version of the Wisconsin grading system (ETDRS score ≥20 in either eye defining the categorical presence of retinopathy).
Nephropathy was evaluated using the 24 hour urinary albumin:creatinine ratio using a Cobas MIRA autoanalyzer (Roche, Nutley NJ). A ratio ≥30 mg/g/24hr was used to define the categorical presence of nephropathy (Kramer & Molitch, 2005) . All laboratory measures were performed at a central study lab at Indiana University.
Neuropathy was evaluated using 10-g monofilament testing on both feet. 
Anthropomorphic and Laboratory measurements
Weight and height were measured with participants wearing light clothing, and the body mass index (BMI) was calculated as weight divided by the square of the height (kg/m 2 ).
Blood pressure was measured twice on the right arm while sitting, using a calibrated mercury sphygmomanometer. The average of these measurements was used for analysis.
Glucose concentrations were determined using a glucose oxidase method (YSI, Yellow Springs, OH). Insulin was measured using a radioimmune assay (Linco Research, St Charles, MO). HbA1c was measured using an immunoturbidometric assay (Roche Diagnostics, Indianapolis, IN). Total and HDL cholesterol and triglycerides were measured using an enzymatic end-point assay (Roche Diagnostics). LDL cholesterol concentration was derived using the Friedewald calculation if the value for triglycerides was <400 mg/dl. Non-esterified fatty acids were measured using a colorimetric method 
Statistical Analysis
Cox proportional hazards models were used to assess the effect of baseline retinopathy on progression of the fasting plasma glucose. We adjusted for relevant metabolic, demographic and anthropometric baseline variables and change in variables in multivariable model. Change was calculated as [Yr1 -Yr0], because this provided both the maximal on-study effect and largest available dataset. A threshold significance value for these univariate relationships of p ≤0.1 was applied to select variables for inclusion in the multivariable models. Multivariable models were first constructed using only baseline variables, and then incorporating baseline and change variables that met these criteria.
All statistical analyses were performed with SAS statistical software 9.4 SAS institute Inc. Cary, NC. Statistical significance was pre-specified at p<0.05.
Results
The initial enrolled cohort of the EDIP trial comprised 216 participants. 196 subjects underwent at least two consecutive quarterly visits after the baseline visit, sufficient for determination of the pre-specified study endpoint. Of these, 2 subjects did not have information on baseline retinopathy. Hence, our final sample consisted of 194 subjects to evaluate the prospective relationship of baseline retinopathy with progression of fasting plasma glucose. Due to censoring at the time of progression (6) and individuals lost to follow-up (42) in the first year, analyses incorporating change in baseline variables to year 1 of follow-up included 164 subjects. After the first year the study retention was much improved, with the majority of censoring coming from progression events. Median duration on study was 30 months.
At the baseline evaluation 24/194 subjects with retinal photographs had retinopathy (12.4%). In this population, the mean (SD) ETDRS scores in right and left eye respectively were 18.9 (16.6) and 17.3 (7.2) respectively among those with retinopathy, and 10.0 (0.0) and 10.0 (0.07) respectively among those without retinopathy. The scores for the worst eye among those meeting criteria for retinopathy were 23.7 (14.6), and the distribution of pairs of scores for both eyes were 10/10 n=168; 20/10 n=22; 20/20 n=2; and >20/20 n=2. These 194 subjects did not differ in key anthropomorphic or metabolic variables from the complete set of subjects included at initiation of the study (not shown). The prevalence of neuropathy among individuals who underwent baseline assessments, regardless of subsequently undergoing randomization, was 19/225 11 evaluable participants (8.4%), and of nephropathy was 10/221 evaluable participants (4.5%). In this population there was little overlap of individuals affected by these conditions: Of 199 individuals with evaluable data for all 3 domains, 51 had evidence of one microvascular disease, 3 had two such conditions and none had all three. Table 1 presents demographic, anthropomorphic and metabolic variables at baseline, according to the presence or absence of retinopathy at baseline. None of these variables differed by presence or absence of retinopathy at baseline. Subjects with neuropathy at baseline had higher weight (113.8 (23.2) vs 96.9 (15.6) kg, p= 0.005) compared to subjects without neuropathy. Subjects with nephropathy at baseline had higher systolic blood pressure (149.0 (17.3) vs 132.5 (17.4), p=0.01) compared to subjects without nephropathy. Notable in this set of analyses were the very low mean HbA1c (6.2%), and a lack of differences in age, fasting plasma glucose, or blood pressure by retinopathy status (Table 1) or neuropathy status (not shown).
In univariate Cox analysis, the presence of retinopathy at baseline was associated with a doubling of risk of progression of fasting plasma glucose (HR 2.02; 95%CI 1.05-3.89, Table 2 ). We next performed multivariable Cox analyses, first adjusting the retinopathy effect for relevant variables one by one ( Table 2 Stage retinopathy in newly diagnosed Type 2 diabetes (mean HbA1c) was associated with lower beta cell responsiveness, insulin resistance, and insulin levels, and elevated fasting and postprandial glucose (Roy Chowdhury et al., 2016). In our study we see an association of retinopathy with progression of fasting plasma glucose, but we found no association found between retinopathy and baseline levels of beta cell function, insulin resistance, and insulin levels. This difference in observed associations is presumably due to the different underlying patient populations, with differing ranges of the variables being compared.
Our observations extend and augment these prior reports. We confirm the prospective relationship of baseline retinopathy lesions with increased risk of progressive dysglycemia, within a group with early screen-detected diabetes. Further, we provide quantification of the strength of the relationship of retinopathy versus other factors that are predictive of glycemic progression. Our study used more rigorous ascertainment of glycemic progression than has been used in prior reports, and applied a researchstandard evaluation of retinopathy using readers blinded to participant characteristics.
By virtue of the strength of our outcome assessments, many of the components of our multivariable analyses were more robustly ascertained than has been possible in the above population studies reporting this association. The mechanism(s) underlying the association of prevalent retinopathy with progressive metabolic worsening are unknown. It is possible that the presence of retinopathy may simply be informing us that the affected individual has experienced a greater magnitude or duration of exposure to elevated glucose levels than is evident in their current glucose values. Since glucose itself is a strongly dominant predictor of progressive dysglycemia in this dataset (Table 2) However, in our population there was no difference in the insulinogenic index or the disposition index at baseline by retinopathy status ( Table 1 ), suggesting that impaired β-cell function may be an insufficient explanation. It is also possible that the presence of retinopathy identifies an individual with an increased microvascular susceptibility to glycemia, such that even modest elevations promote disease progression. A third possibility is that the presence of retinopathy is due to some shared factor arising with the dysmetabolic state that is common to vascular and metabolic worsening (i.e. a 'common soil'). Our analyses do not distinguish among these three possibilities but it is worth noting that the observations in adjusted univariate analyses suggest that the effect of retinopathy on risk of progression may be independent of glucose. Further evidence for a glucose-independent relationship is the lack of parallel observations in our cohort in the association of nephropathy and neuropathy with progression of glucose, although factors such as detection sensitivity and glucose exposure thresholds for disease may be masking true underlying associations. Future studies will need to be designed to specifically to address these questions.
Limitations
The current evaluations are post-hoc analyses of data collected in the context of a clinical trial, and therefore must be viewed as hypothesis-generating. The randomized treatment did not affect the relationship between retinopathy and progression of fasting glucose, but nevertheless this dataset differs from more traditional epidemiologic evaluations of these prospective relationships. The methodologies used for detection and quantification of retinopathy and nephropathy were arguably more sensitive than the standard methods used to detect and quantify neuropathy. Nevertheless, the methods used for retinopathy and nephropathy were of high quality and all methods are parallel to those used in clinical practice, helping ensure that these observations can be interpreted in the context of routine clinical observations. The reduced number of subjects with evaluable data for analyses incorporating Year 1 data is in part an artifact of the study design, where subjects who met the study endpoint were no longer followed. Despite this a large majority of the original enrollees had data evaluable for these analyses, and this subgroup was clearly representative of the baseline cohort. On this basis we conclude that these analyses are representative of individuals with similar degrees of dysglycemia. The notion of assessing retinopathy as a biomarker or risk factor for diabetes has some appeal in that it is relatively simple, non-invasive, and well tolerated. Nevertheless, such an effort would require including retinopathy assessments, with associated resource needs and costs, in the overall risk factor profile of individuals being assessed for risk of glycemic worsening. This may not be feasible or realistic in the general population with current methods, but could be of value in clinical trials of diabetes prevention or β-cell function preservation.
Conclusions
In this population with early, screen-detected type 2 diabetes, we found that the presence of retinopathy lesions at baseline was associated with a two-fold increased risk of progression of fasting plasma glucose. Other microvascular disease measures that including reduced monofilament sensation and elevated urinary albumin:creatinine ratio at baseline were not predictors of progression of fasting plasma glucose, although 18 the prevalence of these conditions was low in this population which presumably limited our power for demonstrating such relationships even if they truly existed. Early detection of retinopathy may help individualize more aggressive therapy to prevent progressive metabolic worsening in early diabetes.
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